Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: Study of real-world outcomes in modified Mayo Stage IIIa/b cardiac AL amyloidosis finds ECOG PS ≤1, NYHA FC ≤2, achieving heme response ≥VGPR and cardiac response ≥PR after 1st-line treatment portended a good prognosis.”
Proceed to the article.
Source: Robert Orlowski/X